In the KEYNOTE-001 study, NSCLC patients whose tumors expressed PD-L1, as assessed by immunohistochemistry, in >50% of the tumor cells had better response rates to pembrolizumab than patients with lower PD-L1 expression levels [128]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.